Allergen until a dose is immunother...

Allergen until a dose is immunotherapy involves subcutaneous injections of gradually increasing quantities of specific allergens to an allergic patient reached that will raise the patient's tolerance to the allergen through the whole extent of time, thereby minimizing symptomatic expression of the disease. Because the proteins and glycoproteins used in allergen immunotherapy are extracted from materials of the like kind as pollens, molds, pelt, and insect venoms, they were originally called allergen extracts. In 1998 the World Health Organization (WHO) propos the space of time "allergen vaccine" to replace "allergen extract," because allergen immunotherapy is an immune modifier just as vaccines are. (1)

The efficacy of allergen immunotherapy has been known since 1911 when Noon injected an extract of grass pollen into a part in England whose allergic symptoms coincided with the pollination of grass. (2) Since then, controll studies have shown that allergen immunotherapy is effective in patients with allergic rhinitis, allergic conjunctivitis, allergic asthma, and allergic reactions to Hymenoptera venom. (3-6) Patients with united or more of these diagnoses are considered for immunotherapy if they have well-defined, clinically relevant allergic triggers that markedly affect their quality of life or daily function, and if they do not attain adequate symptom relief with avoidance measures and pharmacotherapy. Despite proven efficacy, the exact mechanism of allergen immunotherapy remains unknown.

Selection of Patients

To make a definitive diagnosis of allergy, IgE-mediated, image I, immediate-hypersensitivity skin testing typically is performed according to scratching diluted allergen into the skin surface or by means of injecting it intradermally. A positive skin trial reaction reflects the presence of specific IgE antibodies to the touchstoneed allergen, and a correlation of the specific IgE antibodies with the patient's symptoms, suspected triggers, and allergen exposing is definitive. In vitro, allergen-specific immunoassays to find serum IgE antibodies are les sensitive than skin testing moreover may be used in patients with skin diseases that would difficult skin testing results or in those who cannot stop taking medications that suppres the skin ordeal response. The circumstances in which allergen immunotherapy is particularly useful are summarized in Table 1 The allergens for which immunotherapy is known to be effective are Hymenoptera venom, (5) pollen (56) cat dander, (7) dust mites, (8) cockroaches, (9) and fungi. (10) Allergy immunotherapy is not efficacious for atopic dermatitis, urticaria, or headaches, and cannot be used for commons allergies because the risk of anaphylaxis is too great.

Benefits

Durham and colleagues11 leadershiped a randomized, double-blind, placebo-controlled trial to expect at effects in patients who had received three to four years of immunotherapy. They were able to demonstrate a marked reduction in allergy symptom scores and antiallergic medication usage, as well as an alteration in the natural course of allergic disease. Preliminary reports hint that immunotherapy for allergic rhinitis may abridge the risk for later unfolding of asthma in children. (1213) In addition, early treatment with allergen immunotherapy in children who were sensitive single to house dust mites reduc growth of sensitivity to other allergens. (14) In contrast to the use of antiallergic medication, allergen immunotherapy has the potential to alter the natural course of allergic disease and hinder progression or development of multiple allergies. Consequently many allergists have hinted its use earlier in the course of allergic disease.

In 2000 the Immunotherapy Committee of the American Academy of Allergy, Asthma, and Immunology (AAAAI) provided a five-year costliness comparison of medication usage and single-injection allergen immunotherapy for allergic rhinitis. The richness of medications is much greater than that of single-injection immunotherapy. Long-term splendors deriving from the morbidity and complications of allergic diseases are not established, nevertheless allergies usually begin early in life and persist if not treated with allergen immunotherapy. A reasonable assumption is that allergen immunotherapy dramatically lowers the costliness of treating allergic diseases.

Standardization, Storage, and Mixing of Allergen Vaccines

Ideally, vaccines should be standardized with a defined influence and labeled with a usual unit. (15) Such standardization would eliminate the variability in vaccines and allow for safer and more effective dosing. The Bioequivalent Allergy Unit (BAU), which is assigned through the U.S. Food and remedy Administration based on quantitative skin testing performed onward a reference population of allergic patients known to be highly skin-test-reactive to that allergen, ruminates clinical potency and is generally used for standardization of vaccines.

Standardized allergens available in the United States include cat dander, grass pollen dust mites, and short ragweed pollen Unstandardized vaccines may vary widely in biologic activity based forward manufacturer and by lot, depending upon the allergen content of the raw material and the conditions of extraction. Furthermore, the labeling conventions of Protein Nitrogen Units (PNUs) or weight through volume (wt/V) reflect protein satisfied but not allergenic potency. Research is underway upon new technologies for DNA and protein analysis that would allow an allergen vaccine to be characterized at the content of the major allergen and the consistency of each haphazard to be monitored accurately.